This interesting book explores ethical issues of human genetic databases, otherwise known as biobanks, across Europe and North America. Its author, Bernice Elger, provides a detailed account of existing guidelines of health data collection and biomedical research. Most issues of controversy concern consent, confidentiality, access to genetic databanks, feedback to participants and benefit sharing. Therefore, in order to deal with these issues, the book is divided into five chapters.
The introductory chapter provides a general background to human genetic databases. A number of these databases began after the completion of the Human Genome Project (HGP). Therefore, their challenges have been to match genotypes against phenotypes at the same time as surviving in the real world. Scientists and the pharmaceutical industry (or big pharma) place high hopes in biomedical research that uses genetic data stored in biobanks. This is because they expect and/or imagine an increase in patents, a reduction in the financial cost of drug discovery and the development of personalised medicine. However, this type of research raises crucial ethical questions, especially when genetic data are combined with information on individuals' health, lifestyle and genealogy. More and more countries in Europe and North America are addressing these issues through national and international guidelines such as the International Ethical Guidelines for Biomedical Research (Council for International Organisations of Medical Sciences), the Directive 95/46/EC (European Parliament and the Council), and the Declaration on Ethical Considerations regarding Health Databases (World Medical Association).
Although the majority of guidelines are based upon deontological principles and underlying values, this book seems to take a consequentialist position, focusing on morally legitimate interests. Elger argues that ethical problems concerning databases have not been sufficiently discussed, let alone resolved. Her argument is not entirely convincing, since there have been several attempts to deal with such problems. What is certain is that discussing or describing ethical problems does not necessarily mean resolving them. For this reason there are no clear regulatory frameworks for governing biobanks. Instead there are different and sometimes conflicting guidelines concerning collection, storage and research about biological data and lifestyle information. The introductory chapter of this book is important not only because it warns readers from the outset about the controversy surrounding biobanks but also because it provides useful definitions of and distinctions between key concepts. For instance, Elger clearly defines biobanks or genetic databases, as collections of human samples containing DNA or collections composed of the information contained in DNA. This information is linked to other data or information about the donors of the samples.
The second chapter of this book discusses the ethical problems of existing biobanks, including that of Iceland, the UK Biobank, the biobank established in Estonia and the Swiss Pediatric Oncology Group (SPOG) Tumour Bank. Unsurprisingly, Elger begins with the Icelandic biobank, recognising that it is one of the examples which has been discussed by a great number of specialists. However, she insists it is important to look at the details of the Icelandic experience. Historical investigation into the process of development of the Icelandic project reveals that, although it was initiated by the US corporation deCode, it was supported by the Icelandic government. The legislation passed in May 2000, the so called Biobanks Act, was problematic. According to Elger (p. 15), the Act:
‘makes it theoretically possible for the oversight committee to allow samples taken in other contexts, and even samples of people who have withdrawn their assumed consent to be included in any of deCode's databases if the benefits outweigh the inconveniences.’
Indeed, this has provoked huge opposition and resulted in about 20,000 Icelanders withdrawing from the biobank. Criticism has focused not only on the ethical problems of the biobank but also on its scientific value, with some scientists expressing doubts about the importance of the project. Elger does not go into the details of this criticism: her account is more descriptive than analytical. What Elger does is to reflect on ethical issues such as confidentiality, informed consent and fairness, insisting that their importance derives from the consequentialist argument: if patients are not confident about informed consent, confidentiality and fairness, they will not reveal relevant health and lifestyle information. In fact, Elger almost ignores the fact that there are also non-consequentialist arguments. These are rights-based arguments (Dworkin, Reference Dworkin1977) of privacy and self-ownership, which also provide guidance on issues such as consent, confidentiality and the fair distribution of the benefits of biobanking.
Elger moves on to the UK Biobank, stressing that the ethical and legal issues are similar to those raised in the Icelandic case. However, the difference is that the UK Biobank has learned from the Icelandic experience, especially with regard to privacy and informed consent. The aim of the UK Biobank project has been to collect health data and biological samples from 500,000 individuals aged between forty-four and forty-nine. The assumption is that ten years from the beginning of the study, over 11,000 participants will have developed diabetes mellitus, 8,000 myocardial infection, and almost 15,000 breast, colorectal or prostate cancer. A Biobank company was set up to manage the samples and in 2007 the recruiting process started. Elger examines public attitudes towards participating in the UK Biobank, observing that the UK public had a more positive attitude to genetic research than the public in other countries. This is due to UK trust in the national health system (NHS) and the welfare state. However, despite these positive attitudes, the Biobank still raised concerns among scientists and stakeholders, including benefit sharing, consent, confidentiality, commercialisation, ownership and fairness. Although the debate is ongoing, Elger risks the conclusion that the UK Biobank is more legitimised than other biobanks.
Elger continues her inquiry with the Estonian Gene Bank. Like the UK Biobank, the Estonian project tried to avoid ‘mistakes’ similar to those made in Iceland. The Estonian Biobank began with a pilot in 2002 and by the end of 2003 about 10,000 participants had been recruited. The Estonian parliament passed regulatory legislation, according to which informed consent is required for the collection of samples while the use of coercive means is prohibited. Elger observes that one important difference from the UK Biobank is that participants in Estonia were told from the beginning that they had the option of learning about their own risks of developing diseases. Similarly to the UK Biobank, the founders of the Estonian project commissioned studies of public attitudes to biobanking. Ethical and legal objections have been expressed as regards inducement, absence of sufficient debate before taking the political decision, unclear benefits, the lack of an independent ethics committee, participation of children, confidentiality, privacy and informed consent.
Finally, Elger examines the case of SPOG Tumour Bank. The aim of this biobank is to provide a basis for advances in molecular genetic cancer research in Switzerland. The project began in 2000 with the objective of investigating whether genetic particularities represent relevant steps in the development of these tumours. Elger stresses that so far there has been neither public debate about the project nor evaluation of public attitudes. However, there have been concerns around issues of commercialisation, inducement, informed consent, confidentiality, privacy and access to data. Comparing the four biobanks, Elger concludes that most of them have had to adapt important ethical and legal aspects. Only the UK Biobank that started later was able to avoid repeating the same mistakes of the previously established biobanks. Elger observes that the governance frameworks used by the four biobanks have over time become closer to each other.
The third chapter is arguably the most interesting and intellectually stimulating. The focus here is on the ethical debate about principles, values and interests. Elger asks whether traditional frameworks for health research ethics provide the necessary guidance for using samples and data, or whether there is a need to substitute or complement these frameworks. To answer this question, she focuses on ‘classical’ international guidelines for health research ethics. Elger begins with ethical principles discussed in the so-called Belmont Report (1979). These principles include respect for autonomy, beneficence, non-maleficence and justice. The Council for International Organisation of Medical Sciences' International Ethical Guidelines (2002) clearly endorse them, promoting ethical universalism. However, this universalism has been criticised by developing countries' experts who claim that the ethical codes of developed countries should not be imposed on the rest of the world. Elger also discusses the Declaration of Helsinki and the Convention on Human Rights and Biomedicine (i.e. the Bioethics Convention). These documents use the term ‘principle’ instead of the term ‘guideline’. Principles of bioethics prioritise the wellbeing of the human subject over the interest of science and society. This deontological approach to bioethics only allows restrictions on human rights for the prevention of crime, protection of public health, etc. To put it another way, the Bioethics Convention allows restrictions on human rights only for the sake of avoiding a moral catastrophe. In contrast, the guidelines of the Nuffield Council on Bioethics are in line with a consequentialist approach to governance of human genetic databases.
Elger correctly observes that the ideal of ‘justice’ is central to the majority of guidelines relevant to the establishment and use of human genetic databases. In her view, justice requires two things: first, participants should benefit from the research; second, benefits and burdens should be distributed equally. Principles of justice include traditional principles of non-harm, informed consent and benefit sharing. But there are also new principles involved in the just guidance of biobanks: solidarity and equity. Elger contrasts traditional principles of human genetic databases with new ethical frameworks. The latter require justice in the distribution of benefits from research. Elger criticises new principles such as solidarity, arguing that they are not ‘useful to resolve ethical problems associated with research using genetic databases’ (p. 89). Elger argues solidarity has two meanings: first as a justification for limiting individual rights and underplaying consent in the name of the common good; second, it is used in the opposite way in order to promote greater protection of donors through consent. In fact, Elger's problem with the principle of solidarity is that there are no concrete types of solidarity that can be legally enforced. In this argument Elger seems to overlook the fact that solidarity can be promoted as a moral principle independent of legal enforcement. In this sense, she presents a rather utilitarian view of morality, i.e. the view that moral obligations are just legal obligations which contribute to maximisation of the aggregate utility (Bentham, Reference Bentham, Burns and Hart1970; Lyons, Reference Lyons and Waldron1984).
It is not surprising then that Elger rejects the principle-based approach used in the majority of guidelines and instead defends a utilitarian approach based on interests. According to her:
‘An approach based on interests could have several advantages over a principle-based approach … First, an interest-based approach provides a direct way to integrate the reality of pluralistic society into ethical deliberation … Second, an interest-based approach is useful in order to describe more clearly what is meant by the idea of an interest in society. (p. 92, emphasis added)
Elger does not seem to take into account the fact that utilitarian and pluralist conceptions of ethical deliberation fail to point towards an ethical consensus about human genetic databases.
However, what is extremely useful and interesting is that Elger, at the end of this chapter, presents a series of tables where she examines guidelines with explanations. Thus she provides the reader with an overview of the historical development of the principles guiding human genetic databases.
The fourth chapter of the book discusses the controversy over issues of consent and confidentiality. Elger begins the chapter by recognising that the problem is not whether consent is needed in research involving human genetic databases, but rather what form of consent is needed. Elger distinguishes between two extreme positions: ‘blanket consent’ and ‘new informed consent’. The former allows use of a sample for genetic research in general while the latter requires informed consent for each new use of a sample for genetic research. There are also intermediate positions: general, broad or unrestricted consent, as well as semi-blanket consent.
Elger argues that the debate about consent unfolds in two directions: first, classical informed consent at the outset of a project is not enough and should be supplemented by community consent; second, the standard of informed consent should be relaxed to allow for a more general consent for future projects. Elger is critical of both these directions that the debate has taken. In any case, she correctly recognises that consent is a complex problem. Controversy arises because of the difficulty of agreeing on what precisely constitutes anonymous or anonymised samples. According to Elger (p. 164) three points need to be confirmed:
‘First, a principal problem of DNA is that it is never completely anonymous, but permits the identification of the individual or family …
Secondly, any information stored without or together with samples differs in the degree of identification even if names and addresses are stripped …
Thirdly, a number of guidelines differentiate between irreversibly and reversibly anonymised samples and information.
Elger also addresses the issue of confidentiality, arguing that it is important considered from the points of view of respect for persons and their information, and trust in public health and research. There are several risks associated with confidentiality and privacy but probably the most important is that:
‘even if data are completely and irreversibly anonymised, they might still threaten the privacy and confidentiality not of individuals, but of groups – as far as information or samples permit identification of ethnic, racial or other group characteristics.’ (p. 172)
Elger's study of various guidelines reveals different terminology in relation to, and meanings of, confidentiality and privacy rules. She presents these differences in a useful table in this chapter. She also examines different forms of confidentiality as well as their limits. Access to data for the police, the research community and commercial organisations is also examined. Several guidelines deal with these issues. Elger describes these guidelines in detail, providing information about the rules governing confidentiality in biobanks. However, her study is rather uncritical of various guidelines. Also, it is ahistorical in the sense that Elger does not consider the importance of historical processes in the development of guidelines. Instead she treats almost all guidelines as if they were established on the same grounds of moral and legal justification. Elger recognises that confidentiality has limits:
‘[I]t is impossible to exclude completely accidental violations of confidentiality and illegitimate access. In addition, access to the data and samples of a biobank is legitimate and even ethically required in some circumstances.’ (p. 208).
In the second part of her chapter, Elger also discusses guidelines which address the question of whether participants should be informed about the results of research projects involving genetic databases. She points out that classical guidelines for biomedical research take an explicit position. For example, the Convention of Human Rights and Biomedicine implies a right to know: everyone is entitled to know any information about his/her health unless he/she wishes not to be so informed. However, more recent biobank guidelines disagree over this. Elger presents the arguments for and against the right to know. Unfortunately, her account remains descriptive and she does not go far enough towards providing an in-depth analysis of different philosophical and/or legal positions.
Elger finishes this chapter with the issue of benefit sharing. First of all, she recognises that this issue has been controversial for many years. The concept of benefit sharing has not yet been clearly defined. Some guidelines state clearly that participation in research should not include payment. In contrast, some other guidelines stress that some form of financial benefit for research subjects is necessary. In any case, Elger is right to point out that benefit sharing is an issue of distributive justice and therefore should be dealt with as such. One strong argument in favour of the distribution of benefits is that the human genome is a common good, and benefits resulting from genetic research should be made equally available to all human beings. Another argument is that human tissue is private property and therefore individuals should be allowed to make a profit from their tissue. Extreme positions against these arguments emphasise that human material is not a commodity that can be sold in the market. Elger brilliantly classifies the different positions for and against benefit sharing. In her conclusion to this chapter she takes a position against benefit sharing in countries with universal access to health care, arguing that in principle everyone will receive benefits through health care. The same does not apply, however, in developing countries. For this reason, in these countries, health institutions are justified in asking for global benefit sharing if pharmaceuticals use public resources such as hospitals or biobanks.
The last chapter of this book is the shortest. Here Elger summarises the lessons learnt throughout the past twenty years about the development of ethical guidelines in Europe and North America. She also discusses future challenges. Elger concludes that there is an ‘impressive degree of agreement’ (p. 251) on many basic questions addressed in the ethical guidelines of biobanks. Although such guidelines are from different times and contexts, they appear to be similar in substance.
This book, despite its descriptive approach to the ethics of genetic databases, is a comprehensive piece of work in the governance of new life sciences innovation. Therefore, it should be read by academics, policy-makers and all those who work in this field.
